Experience of Application Piribedil (Pronoran) in Patients With Coronary Heart Disease After Coronary Artery Bypass Surgery

Abstract

ФГБОУ ВО Красноярский государственный медицинский университет имени проф. В.Ф. Войно-Ясенецкого Министерства здравоохранения РФ, ректор-д.м.н., проф. И.П. Артюхов; кафедра поликлинической терапии, семейной медицины и ЗОЖ с курсом ПО, зав.-д.м.н., проф. М.М. Петрова. O.V. Eremina Krasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky Aim of the research. To study the influence of piribedil (pronoran) to the state of cognitive functions in patients with coronary heart disease after coronary bypass surgery. Materials and methods. It were studed 64 patients with coronary heart disease. All patients were divided into two groups. In the main group (n = 32) in addition to the therapy was prescribed pronoran (piribedil) at a dose of 50 mg once daily for 3 months. The comparison group (n = 32), patients in the postoperative period received standard therapy. There were assessed cognitive function in patients before surgery, on the 10th day, after three and six months after coronary bypass surgery. The article presents a case of a patient rehabilitation with coronary heart disease, mild cognitive disorders after coronary bypass surgery. Results. In the group of patients during therapy with piribedil in 6 months after coronary artery bypass were noted positive dynamics in almost all tests. Conclusion. Taking into account the authentic improvement the results detected in patients during treatment with piribedilom we can with high probability to assume a positive effect of this drug on memory indexes and attention, psychomotor speed processes.